Background
Adenosine is a purine nucleoside, which modifies different physiological functions, including vascular tone in numerous blood vessels. This effect is a consequence of interaction between adenosine and specific adenosine A 1 , A 2 or A 3 receptors. Still, the relaxant effect of this endogenous nucleoside has been shown on some blood vessels to be mainly dependent on activation of adenosine A 2 receptors that can be located on endothelial or smooth muscle cells. To examine this assumption the aim of this study was to determine the effects of CPCA (a selective adenosine A 2 receptor agonist) on the isolated rat femoral artery and to establish whether potassium channels are involved in this action.
Methods
Experiments were conducted on isolated femoral arteries of male rats. Circular vascular segments were placed in an organ bath with Krebs-Ringer's solution. Concentration-response curves for CPCA were obtained in a cumulative fashion on precontracted artery rings. Tension alterations induced by CPCA were continuously recorded.
Results CPCA (0.1-100 µM) produced endothelium-dependent relaxation. Incubation of DPCPX (a selective antagonist of A 1 receptors, 10 nM) did not influence the control effect of the examined agonist, while SCH 58261 (a selective antagonist of A 2A receptors, 1 µM) significantly reduced CPCA-induced vasodilatation. The maximal vascular response to CPCA was comparable after denudation and incubation of SCH 58261. In the presence of high K + (100 mM) a significant inhibition of the control CPCA-induced relaxation was recorded. This was not the case after the application of glibenclamide, a blocker of ATP-sensitive K + channels.
Conclusions
CPCA induced an endothelium-dependent vasodilatation of the examined blood vessel by activation of adenosine A 2A receptors, most probably located on the endothelial cells. It can be assumed that the CPCAevoked action was most likely mediated via some endothelium-derived hyperpolarizing factor. However, ATP-sensitive K + channels did not contribute to the overall femoral artery response to CPCA.
